Immunogenic proteins from bordetella pertussis
AssigneeOhio State Innovation Foundation
InventorPurnima DUBEY
Life of this patent
Estimating the term…
Abstract
Recent evidence accumulating over the last decade demonstrates that generation of CD4+ T cells is critical for sustained immunity against Bordetella pertussis. B. pertussis contains hundreds of antigens that are processed and presented on MHC Class II and recognized by CD4′T cells. The present disclosure relates to a vaccine comprising Bordetella pertussis antigen peptides to prevent infection of the Bordetella pertussis bacterium.
Claims21
A pertussis vaccine comprising a BP0205 antigen in combination with at least one additional peptide from a Bordetella pertussis (B. pertussis) bacterium, wherein the BP0205 peptide and the at least one additional peptide are to be presented to an MHC Class II cell and recognized by a CD4+ T cell.
(canceled)
(canceled)
(canceled)
10-19. (canceled)
Dependencies are inferred from the claim text.